Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets
Priscilla Kaliopi Brastianos, Scott L. Carter, Sandro Santagata et al. · Cancer Discovery · 2015
UNLABELLED: Brain metastases are associated with a dismal prognosis. Whether brain metastases harbor distinct genetic alterations beyond those observed in primary tumors is unknown. We performed whole-exome sequencing of 86 matched brain metastases, primary tumors, and normal tissue. In all clonally related cancer samples, we observed branched evolution, where all metastatic and primary sites shared a common ancestor yet continued to evolve independently. In 53% of cases, we found potentially clinically informative alterations in the brain metastases not detected in the matched primary-tumor sample. In contrast, spatially and temporally separated brain metastasis sites were genetically homogenous. Distal extracranial and regional lymph node metastases were highly divergent from brain metastases. We detected alterations associated with sensitivity to PI3K/AKT/mTOR, CDK, and HER2/EGFR inhibitors in the brain metastases. Genomic analysis of brain metastases provides an opportunity to identify potentially clinically informative alterations not detected in clinically sampled primary tumors, regional lymph nodes, or extracranial metastases. SIGNIFICANCE: Decisions for individualized therapies in patients with brain metastasis are often made from primary-tumor biopsies. We demonstrate that clinically actionable alterations present in brain metastases are frequently not detected in primary biopsies, suggesting that sequencing of primary biopsies alone may miss a substantial number of opportunities for targeted therapy.
Cited by 1,082 works. doi:10.1158/2159-8290.cd-15-0369 Open-access PDF
Authors
- Priscilla Kaliopi Brastianos
- Scott L. Carter
- Sandro Santagata
- Daniel P. Cahill
- Amaro N Taylor-Weiner
- Robert T. Jones
- Eliezer M. Van Allen
- Michael S. Lawrence
- Peleg Moshe Horowitz
- Kristian Cibulskis
- Keith Lloyd Ligon
- Josep M. Tabernero
- Joan Seoane
- Elena A. Martínez-Sáez
- William T. Curry
- Ian F. Dunn
- Sun Ha Paek
- Sung‐Hye Park
- Aaron McKenna
- Aaron Chevalier
References
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
- Comprehensive genomic characterization defines human glioblastoma genes and core pathways
- A framework for variation discovery and genotyping using next-generation DNA sequencing data
- Integrated genomic analyses of ovarian carcinoma
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- A Randomized Trial of Surgery in the Treatment of Single Metastases to the Brain
- Distant metastasis occurs late during the genetic evolution of pancreatic cancer
- Absolute quantification of somatic DNA alterations in human cancer
- Tumour evolution inferred by single-cell sequencing